Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
WINTER SPRINGS, Fla., Oct. 18, 2016 -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that the Company will release its 2016 third quarter financial results before the market opens on Friday, October 28th. IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.
Individuals interested in listening to the conference call may do so by dialing 1-844-413-1781 for domestic callers, or 1-716-247-5767 for international callers, and entering reservation code 2986888.
The conference call will also be available real-time via the Internet at www.iradimed.com/en-us/investors/index.php and selecting Events & Presentations. A recording of the call will be available on the Company’s website for 90 days following completion of the call.
About IRADIMED CORPORATION
IRADIMED CORPORATION is the only known provider of non-magnetic intravenous (IV) infusion pump systems that are specifically designed to be safe for use during magnetic resonance imaging (MRI) procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency (RF) interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely-designed non-ferrous parts and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated in order to remain immobile during an MRI scan.
Media Contact: Chris Scott Chief Financial Officer IRADIMED CORPORATION (407) 677-8022 [email protected]
